Glassy Mountain Advisors Inc. Purchases New Shares in IQVIA Holdings Inc. $IQV

Glassy Mountain Advisors Inc. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to its most recent disclosure with the SEC. The firm purchased 17,769 shares of the medical research company’s stock, valued at approximately $4,005,000.

Other large investors have also added to or reduced their stakes in the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA during the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. grew its holdings in IQVIA by 1,340.0% during the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 134 shares in the last quarter. International Assets Investment Management LLC acquired a new stake in IQVIA during the 4th quarter valued at $27,000. Westside Investment Management Inc. boosted its stake in IQVIA by 219.6% during the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Finally, Measured Wealth Private Client Group LLC bought a new position in IQVIA during the 3rd quarter valued at $30,000. 89.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have commented on IQV shares. Mizuho set a $215.00 price objective on shares of IQVIA in a research note on Monday, February 23rd. Weiss Ratings downgraded shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research note on Monday, May 4th. JPMorgan Chase & Co. reduced their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a research note on Friday, February 6th. Barclays upgraded shares of IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price objective on the stock in a research note on Friday, March 6th. Finally, Truist Financial reduced their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating on the stock in a research note on Thursday, February 19th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $224.13.

IQVIA Trading Up 0.8%

IQVIA stock opened at $182.12 on Thursday. The firm’s 50-day moving average is $171.35 and its 200-day moving average is $195.26. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 1 year low of $143.00 and a 1 year high of $247.04. The company has a market cap of $30.40 billion, a P/E ratio of 22.57, a PEG ratio of 1.73 and a beta of 1.21.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the firm posted $2.70 EPS. The company’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities analysts expect that IQVIA Holdings Inc. will post 11.58 earnings per share for the current year.

IQVIA announced that its Board of Directors has authorized a stock buyback plan on Thursday, May 7th that permits the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s leadership believes its stock is undervalued.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.